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Expression of the ubiquitin-proteasome pathway and muscle loss
in experimental cancer cachexia
J Khal1, SM Wyke1, ST Russell1, AV Hine1 and MJ Tisdale*,1
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Muscle protein degradation is thought to play a major role in muscle atrophy in cancer cachexia. To investigate the importance of the
ubiquitin-proteasome pathway, which has been suggested to be the main degradative pathway mediating progressive protein loss in
cachexia, the expression of mRNA for proteasome subunits C2 and C5 as well as the ubiquitin-conjugating enzyme, E214k, has been
determined in gastrocnemius and pectoral muscles of mice bearing the MAC16 adenocarcinoma, using competitive quantitative
reverse transcriptase polymerase chain reaction. Protein levels of proteasome subunits and E214k were determined by
immunoblotting, to ensure changes in mRNA were reflected in changes in protein expression. Muscle weights correlated linearly
with weight loss during the course of the study. There was a good correlation between expression of C2 and E214k mRNA and
protein levels in gastrocnemius muscle with increases of 6–8-fold for C2 and two-fold for E214k between 12 and 20% weight loss,
followed by a decrease in expression at weight losses of 25–27%, although loss of muscle protein continued. In contrast, expression
of C5 mRNA only increased two-fold and was elevated similarly at all weight losses between 7.5 and 27%. Both proteasome
functional activity, and proteasome-specific tyrosine release as a measure of total protein degradation was also maximal at 18–20%
weight loss and decreased at higher weight loss. Proteasome expression in pectoral muscle followed a different pattern with increases
in C2 and C5 and E214k mRNA only being seen at weight losses above 17%, although muscle loss increased progressively with
increasing weight loss. These results suggest that activation of the ubiquitin-proteasome pathway plays a major role in protein loss in
gastrocnemius muscle, up to 20% weight loss, but that other factors such as depression in protein synthesis may play a more
important role at higher weight loss.
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Loss of skeletal muscle is a prominent feature of cancer cachexia,
resulting in weakness, immobility and finally death. Body
composition analysis of lung cancer patients who had lost 30%
of their body weight revealed a 75% reduction in skeletal muscle
mass, while visceral proteins were preserved (Fearon, 1992). Loss
of skeletal muscle protein is thought to arise from a suppression of
protein synthesis (Emery et al, 1984) and/or an increase in protein
breakdown and oxidation of amino acids (O’Keefe et al, 1990).
A number of experimental animal tumours have been developed
to study the mechanism of muscle wasting in cachexia. In the
murine MAC16 colon adenocarcinoma model, weight loss occurs
with small tumour burden (less than 0.1% of host weight), and
without a reduction of food and water intake (Beck and Tisdale,
1987), allowing a study of the metabolic components of cachexia.
As in cancer patients, the major components of body weight loss in
the MAC16 model are adipose tissue and skeletal muscle mass.
Loss of skeletal muscle mass arises from a reduction (by 60%) in
protein synthesis and an increase (three-fold) in protein degrada-
tion (Beck et al, 1991). As was found in a rat model of cancer
cachexia (Baracos et al, 1995; Llovera et al, 1997), the major
contribution to the loss of muscle mass in mice bearing the MAC16
tumour appears to arise from an upregulation of the ATP-
ubiquitin-dependent proteolytic pathway (Lorite et al, 1998), as
reflected by increased levels of ubiquitin-conjugated proteins
and increased mRNA levels for the 14 kDa ubiquitin carrier
protein, E2 and the C9 proteasome subunit in gastrocnemius
muscle. However, as with other studies in animals this was only
measured after weight loss had developed, and there have been no
measurements of the expression of the major components of the
ubiquitin-proteasome pathway at different extents of weight loss,
or a comparison between different muscle types to understand if
this pathway totally explains protein degradation. However, a
study in gastric cancer patients showed an increase in expression
of ubiquitin mRNA and proteasome activity compared with
controls, and proteasome activity correlated both with stage of
disease and weight loss (Bossola et al, 2003).
The purpose of the present study was to measure changes in
expression of the key regulatory components of the ubiquitin-
proteasome proteolytic pathway in skeletal muscle with the
development of cachexia in the MAC16 model. Protein degradation
in this model has been shown to increase progressively with
increasing weight loss between 15 and 30%, up to a maximum
increase of 240% at a weight loss of 30% (Smith and Tisdale,
1993a). Expression of mRNA for E2, and the proteasome subunits
C2 and C5, representing a and b subunits of the proteasome
respectively, have been determined in gastrocnemius and pectoral
muscle by quantitative RT– PCR as a measure of the ubiquitin-
proteasome pathway. These are considered to be representative of
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proteasome structural and catalytic subunits indicative of protea-
some expression. Previous studies (Lorite et al, 2001; Whitehouse
et al, 2001) have shown that subunits of the 19S regulator change
in concert with the proteasome a-subunit. As a measure of
ubiquitin conjugation mRNA levels for E214k have been deter-
mined, which was originally suggested to be rate-limiting for
ubiquitin conjugation during starvation (Wing and Banville, 1994),
although studies in E214k knockout mice suggest that it is
nonessential (Adegoke et al, 2002). However, recent data suggest
that the ubiquitin-protein ligases (E3), muscle ring-finger 1
(MURF1); (Bodine et al, 2001) and muscle atrophy F box
(MAFbx)/atrogin-1 (Gomes et al, 2001), may be the rate-limiting
step in various conditions of muscle atrophy including cachexia.
In this study, the expression of some components of the
ubiquitin-proteasome pathway has been monitored with increa-
sing weight loss in gastrocnemius and pectoral muscle of mice
bearing the MAC16 tumour, since some reports (Khal et al, 2005)
suggest that the expression of this pathway in the skeletal muscle
of cancer patients decreases at weight losses greater than 20%.
Measurements of protein levels of proteasome a-subunits and
E214k have also been determined by immunoblotting to ensure that
changes in mRNA are reflected in changes in protein expression.
MATERIALS AND METHODS
Materials
Mouse monoclonal antibody to 20S proteasome subunits a1, 2,
3, 5 and 7 (clone MCP231) was purchased from Affinity Research
Products (Exeter, UK). Rabbit polyclonal antisera to E214k was a
gift from Dr Simon Wing (McGill University, Montreal, Canada).
The antibody detected E214k as a Mr 17 kDa band (Rajapurohitam
et al, 1999). Goat polyclonal antiserum to MURF3 (E3) and
peroxidase-conjugated rabbit polyclonal antisera to goat IgG were
purchased from Abcam Ltd (Cambridge, UK). Mouse monoclonal
anti-PIF antibody was prepared as previously (Todorov et al,
1996). Peroxidase-conjugated goat anti-rabbit and rabbit anti-
mouse secondary antibodies were from Dako Ltd (Cambridge,
UK).
Wizardt mini or maxi preps, used to prepare plasmid DNA
from overnight cultures of bacterial clones, were obtained from
Promega (Southampton, UK), as were the T7 RNA polymerase kit,
RNAsin inhibitor, reverse transcriptase, reverse transcription
buffer and PCR grade magnesium chloride. Taq polymerase and
Hybond C were from Amersham Biosciences UK Ltd (Bucks, UK),
TRI reagent for RNA isolation was purchased from Sigma-Aldrich
Co-Ltd (Dorset, UK), while the oligonucleotide primers were from
MWG Biotech (Ebersberg, Germany). RNA storage buffer was
purchased from Ambion Ltd (Cambridgeshire, UK) and PCR
buffer was from Roche, Switzerland.
Animals
All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed
met the standards required by the UKCCR guidelines (Workman
et al, 1998).
Pure strain NMRI mice were obtained from our own inbred
colony and were fed a rat and mouse breeding diet (Special Diet
Services, Witham, UK). Fragments of the MAC16 colon adeno-
carcinoma, excised from donor animals with established weight
loss, were implanted into the flanks of NMRI mice by means of a
trocar, as described (Beck and Tisdale, 1987). Animals started to
lose weight approximately 10–12 days after transplantation.
Animals were terminated at various extents of weight loss, and
both gastrocnemius and pectoral muscles were removed, and
immediately frozen in liquid nitrogen, and stored at 701C before
further analysis.
Measurement of protein degradation ex vivo
Gastrocnemius muscles were excised from mice bearing the
MAC16 tumour, and with varying extents of weight loss, and
preincubated for 45 min in 3 ml oxygenated (95% oxygen/5%
carbon dioxide) Krebs –Henseleit bicarbonate buffer, pH 7.4,
containing 5 mmol1 glucose and 0.5 mmol l1 cycloheximide.
Protein degradation was determined by the release of tyrosine
(Waalkes and Udenfriend, 1957) over a 2 h period in the absence
and presence of lactacystin (10 mM). Tyrosine release, which was
blocked in the presence of lactacystin, was considered to be
proteasome specific.
Measurement of proteasome activity
The ‘chymotrypsin-like’ enzyme activity of the proteasome was
measured fluorometrically as described by Orino et al (1991).
Muscles were removed from animals with varying degrees of
weight loss and homogenized with a teflon glass homogenizer in
20 mM Tris-HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2 and 1 mM DTT on
ice at 41C. The homogenate was further dissociated by sonication
at 41C, and the sonicate was then centrifuged at 18 000 g for 10 min,
and the supernatant was used to measure enzyme activity by the
release of aminomethylcoumarin (AMC) from succinyl-LLVY-AMC.
The reaction was performed for 1 h at room temperature in 100 mM
Tris. HCl, pH 8.0, and was terminated by the addition of 80 mM
sodium acetate, pH 4.3. The fluorescence of AMC was determined
with an excitation wavelength of 360 nm and an emission
wavelength of 460 nm. The reaction was performed in the presence
and absence of the specific proteasome inhibitor lactacystin, and
only lactacystin suppressible activity was considered to be
proteasome specific. The activity was adjusted for the protein
concentration of the sample, determined using the Bradford assay
(Sigma Aldridge, Dorset, UK).
Quantitative RT–PCR
Total RNA was extracted from muscle using TRI-reagent and
the RNA concentration was determined from the absorbance at
260 nm. To quantitate the mRNA of interest, increasing amounts of
competitor RNA, which differed from the mRNA of interest by
containing a short deletion, were added to 250 ng of total RNA and
coamplified using RT– PCR. The amount of specific mRNA was
calculated from the amount of competitor, when equal amounts of
PCR product were obtained from the competitor and target RNA.
The C2 proteasome subunit mRNA was amplified using the
primer pairs: 50-CGCACGGAGTGCTGGTTGCAC-30 (forward) and
50-GTACGAGCTGATTGAGAACGG-30 (reverse) and corresponds
to positions 176– 187 and 531–552 bp. The competitor primer was
designed to produce a DNA fragment containing a 76-bp deletion
by producing a loop in the DNA during the PCR amplification
process. The sequence of this primer was 50-GTACGAGCTGATT
GAGAACGGCATAACCAGCAATGAGCAGCC-30, which corre-
sponds to the reverse complement of bases 561–552 and 435 –
455 of the mouse C2 gene. The competitor product was 309 bp. The
C5 proteasome mRNA was obtained from the mouse gene using
the primer pairs: 50-TCAACGGAGGTACTGTATTGG-30 and 50-
GCATGGCACTTGCTGAGCC-30 at positions 101– 121 and 496–
514 bp. The competitor primer was designed 117 bp upstream of
the reverse primer producing a product 277 bp long. The sequence
of this primer was 50-GCATGGCACTTGCTGAGCCGCATGG
CACTTGCTGAGCC-30, which corresponds to the reverse comple-
ment of bases 496–514 and 358 – 377 of the mouse C5 gene. The
E214k competitor was obtained from the rat gene using the primer
pairs: 50-CTCATGCGGGATTTCAAGCG-30 and 50-CTCTTCTCA
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TACTCCCGTTTGCAT-30. The competitor primer contained a
111 bp deletion and the sequence was 50-CTCTTCTCATACTCCC
GTTGCATCGCTTCTGCAGGATGTC, which corresponds to the
reverse complement of bases 443–468 and 312 – 321 of the rat gene.
The competitor DNAs were blunt ended and then ligated into a
pET30a vector, which had been blunt-end cut with SmaI restriction
enzyme. The ligated vector was used to transform DH5a competent
cells. Plasmid DNA was prepared from PCR positive clones using
Wizard-mini-prep. Competitor RNA was produced using T7 RNA
polymerase kit, and quantitated using the optical density at
260 nm. Six serial two-fold dilutions were prepared containing
known concentrations of competitor. The particular dilutions used
were selected to span the selected concentration of C2, C5 and
E214k in the sample.
To synthesise the cDNA template, a mixture consisting of 250 ng
target RNA, the particular dilution of the competitor RNA and
0.5mg of random hexamer was incubated at 701C for 5 min in a
thermal cycler (Genetic Research, Instrumentation Ltd, Essex, UK)
and then chilled on ice before the addition of 2.5 ml 5 reverse
transcription buffer, 3 ml of 10 mM each of dATP, dGTP, dCTP,
dTTP, 5 units of RNAsin inhibitor and 1 unit reverse transcriptase
in a total volume of 12.5ml. Incubation was at 371C for 1 h. For the
amplification of the cDNA by PCR, 50 ml of PCR mix was added to
each tube. The PCR mixture contained 1 PCR buffer (without
magnesium) together with 3 mM MgCl2 (E2), 3.5 mM MgCl2 (C5)
and 2.5 mM MgCl2 (C2) together with 1 U Taq polymerase. For the
E2 gene 10 pmol of each of the primers 50-CTCATGCGGGATTT
CAAGCG-30 and 50-CTCTTCTCATACTCCCGTTTG-30 were used,
while for the C5 gene 10 pmol of each of the primers 50-
TCAACGGAGGTACTGTATTGG-30 and 50-GCATGGCACTTGCT
GAGCC-30 were used. For the C2 gene, 20 pmol of each of the
primers 50-CGCACGCAGTGCTGGTTGCAC-30 and 50-GTACGAG
CTGATTGAGAACGG-30 were used. The temperature-cycling
profile for amplification was as follows: 951C for 2 min for one
cycle followed by 951C for 30 s, 581C annealing for 1 min and 721C
extension for 1 min for 30 cycles. Control reactions containing all
components except reverse transcriptase and another without
template were carried out alongside each experiment to show that
the RNA (both target and competitor) had no DNA contamination,
while the second control showed that there was no contamination
in the PCR mixture. Coamplification of E2 target and competitor
produced DNA fragments of 395 and 284-bp, respectively; C2
target and competitor produced 385 and 309-bp fragments and
C5 target and competitor produced 414 and 297-bp fragments,
respectively.
For analysis of results, 15 ml of PCR products were separated on
a 2% (w v1) agarose gel containing ethidium bromide. The gel
images were visualised on a UV transilluminator and photo-
graphed. The intensity of the bands was quantitated using a
Phoretix photo-imager programme. The volumes of the competitor
and target bands were plotted against the known serial dilutions of
the competitor used in the experiment. The amount of the sample
RNA corresponds to the amount of competitor when the ratio of
competitor to target is 1.0.
Western blot analysis
Cytosolic protein (5mg for E2 and 20S proteasome a-subunits) was
resolved on 10% sodium dodecylsulphate, polyacrylamide gels.
Proteins were then transferred to nitrocellulose membranes
(Hybond C), which had been blocked with 5% Marvel in Tris
buffered saline (TBS) at 41C overnight. The primary and secondary
antibodies, peroxidase conjugated either rabbit anti-goat, goat
anti-rabbit or rabbit anti-mouse IgG, were used at a 1 : 1500
dilution. Incubation was for 1 h at room temperature and
development was by enhanced chemiluminescence (ECL) (Amersham).
Blots were scanned by a densitometer to quantitate differences,
and a parallel gel was stained by coomassie blue stain to ensure
equal loading. The intensity of bands was quantitated using
‘Phoretix 1D Advanced’ software as above.
Statistical analysis
Results were expressed as means7s.e.m. of three separate
determinations on different animals. Differences were determined
by one-way analysis of variance (ANOVA) followed by Tukey–
Kramer multiple comparison test. P-values less than 0.05 were
considered to be significant.
RESULTS
The effect of increasing weight loss on expression of C2 and C5
mRNA as well as 20S proteasome a-subunit protein levels, detected
by Western blotting, and gastrocnemius muscle weights of mice
bearing the MAC16 tumour is shown in Figure 1. Although the
monoclonal antibody to the 20S proteasome reacts with six
different a-type subunits, only three bands were apparent at
approximate Mr 29, 32 and 35 kDa (Whitehouse et al, 2001)
(Figure 1A). There was a good correlation between expression of
C2 mRNA (Figure 1C) and proteasome protein (Figure 1B), with a
6–8-fold increase in C2 mRNA with increasing weight loss from
12%, reaching a maximum at 15 –20% weight loss. Although C2
mRNA expression at 25–27% weight loss was significantly
enhanced above that found in animals without weight loss
(Figure 1C), it was significantly decreased (Po0.05) compared
with animals exhibiting 20% weight loss. In contrast, expression of
C5 mRNA was significantly increased (by two-fold) at all weight
losses (Figure 1D), with no significant difference between animals
with 7.5% weight loss and those with 27% weight loss. Gastro-
cnemius muscle weight was directly proportional to total body
weight loss, showing progressive loss of skeletal muscle as the
cachexia progresses (Figure 1E). Proteasome functional activity in
gastrocnemius muscle as determined by the ‘chymotrypsin-like’
enzyme activity, the dominant catalytic activity of the b-subunits
of the proteasome, was found to follow a similar change with
weight loss as expression of protein and mRNA of proteasome a-
subunits, with an initial increase with weight loss up to 20%
followed by a decrease at higher weight loss (Figure 1F).
The effect of progressive weight loss on the expression of the
ubiquitin conjugating protein E2 in gastrocnemius muscle
followed a similar pattern to that observed with proteasome
a-subunits (Figure 2). Thus, expression of E2 mRNA was increased
two-fold in gastrocnemius muscle of mice with 12% weight loss
and remained elevated up to 20% weight loss (Figure 2C). The
expression of E2 mRNA in gastrocnemius muscle of mice with
25 and 27% weight loss was not significantly different from that
in mice without weight loss (Figure 2C). The expression of E214k
protein, detected by Western blotting, followed a similar pattern
reaching maximal expression at 15–17% weight loss (Figure 2A,
B). Proteasome-specific protein degradation in gastrocnemius
muscle, determined by the release of tyrosine in the presence of the
specific proteasome inhibitor lactacystin (Fenteany and Schreiber,
1998), also peaked between 17 and 20% weight loss and then
decreased at higher weight loss (Figure 2D). These results suggest
that the ubiquitin-proteasome proteolytic pathway plays a minor
role in the degradation of proteins in gastrocnemius muscle at
weight loss greater than 20%.
Proteasome functional activity in pectoral muscle followed a
similar pattern to that found in gastrocnemius muscle (Figure 3A)
peaking at weight loss between 18 and 22%. Expression of mRNA
for the catalytic b subunit (C5) also peaked at weight loss between
17 and 25% with a decrease at higher weight loss (Figure 3B).
However, expression of mRNA for the proteasome a-subunit C2
(Figure 3C) as well as protein expression of a-subunits (Figure 3D
and E) increased with increasing weight loss with no evidence for a
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maximum. As with gastrocnemius muscle there was a linear
correlation between pectoral muscle weight and total body weight
loss (Figure 3F). Expression of E2 mRNA was little changed with
increase in weight loss in pectoral muscle (Figure 4), with a
significant increase in expression only being seen in animals with
27% weight loss. This suggests that E2 may not be a rate-limiting
step in proteasome proteolysis in this muscle.
DISCUSSION
Skeletal muscle contains multiple proteolytic pathways for
intracellular protein catabolism. Of these, the lysosomal system,
including cathepsins B, D and H, is mainly concerned with the
digestion of extracellular proteins, although some cytosolic
proteins are engulfed in autophagic vacuoles that fuse with
lysosomes and are degraded (Dice, 1990). The cytosolic calcium-
activated pathway (calpains) appears to play an important role in
tissue injury, necrosis and autolysis (Lecker et al, 1999). These two
processes have been suggested to contribute less than 15– 20%
towards total protein breakdown in muscle (Attaix et al, 1998;
Lecker et al, 1999) and do not breakdown myofibrillar proteins
(Lovell et al, 1986). However, the calcium/calpain pathway has
been suggested to release myofilaments from the sarcomere in an
early and perhaps rate-limiting component of the catabolic
response in muscle (Hasselgren and Fischer, 2001). Further
catabolism of the actin and myosin released from the myofilaments
is considered to occur via the ubiquitin-proteasome proteolytic
pathway.
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Figure 1 (A) Expression of 20S proteasome a-subunits in soluble
fractions of gastrocnemius muscles of mice bearing the MAC16 tumour and
with different extents of weight loss, as detected by immunoblotting. (B)
Densitometric analysis of band intensities in (A) reported in arbitary units.
(C) Expression of C2 mRNA and (D) expression of C5 mRNA in
gastrocnemius muscle from mice with different extents of weight loss.
Differences from animals without weight loss are expressed as a, Po0.05,
b, Po0.01 and c, o 0.001. (E) Relationship between weight of
gastrocnemius muscle and percentage weight loss. (F) Proteasome
proteolytic activity, as measured by the ‘chymotrypsin-like’ enzyme activity,
in gastrocnemius muscle of mice with different extents of weight loss. The
symbols for significance are the same as in (D).
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Figure 2 (A) Expression of E214k in soluble extracts of gastrocnemius
muscles from mice bearing the MAC16 tumour and with different extents
of weight loss, as detected by immunoblotting. (B) Densitometric analysis
of band intensities in (A) reported in arbitary units. (C) Expression of E2
mRNA in gastrocnemius muscle from mice with different extends of weight
loss. (D) Total protein degradation, as measured by tyrosine release, in
gastrocnemius muscle of mice with different extents of weight loss. The
figures represent protein degradation inhibited by lactacystin (10 mM).
Differences from animals without weight loss are expressed as b, Po0.01
or c, Po 0.001.
Proteasome expression in skeletal muscle in cachexia
J Khal et al
777
British Journal of Cancer (2005) 93(7), 774 – 780& 2005 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
In this process, substrates are marked for degradation through
the attachment of a polyubiquitin chain by a series of enzymatic
steps mediated by the ubiquitin-activating enzyme (E1), the
ubiquitin-conjugating enzyme (E2) and the ubiquitin-protein
ligases (E3) (Lecker et al, 1999). The polyubiquitinated substrate
then enters the proteolytic chamber of the 26S proteasome, where
it is unfolded and cleaved to short oligopeptides having mean
lengths of 6–9 residues (Kisselev et al, 1999). The proteasome is a
tube-like structure appearing as a stack of four rings; two outer
a-rings and two inner b-rings in order of abba (Lecker et al, 1999).
Proteolytic activity is found on the b-subunits of the proteasome.
Most studies in cancer patients with weight loss of 10% or
higher have suggested that the ubiquitin-proteasome pathway
in skeletal muscle shows an increased expression and activity
(Williams et al, 1999; Bossola et al, 2003). However, a study of lung
cancer patients referred for curative resection and with a weight
loss of only 2.9% showed no increase in expression of components
of the ubiquitin-proteasome pathway, while mRNA levels of
cathepsin B in skeletal muscle were much higher (Jagoe et al,
2002). This suggests that activation of the ubiquitin-proteasome
pathway may only occur when weight loss becomes substantial,
although Bossola et al (2001) reported an increase in ubiquitin
mRNA in skeletal muscle of patients when the weight loss was only
5.674.9%.
In this study, we have measured the expression of one a (C2)
and one b-subunit (C5) of the proteasome during the progression
of loss of gastrocnemius and pectoral muscle in the murine MAC16
cachexia model, as a representative of proteasome structure and
function. We chose these genes since protein breakdown in cancer
cachexia has been suggested to require increased gene expression
of proteasome subunits (Temparis et al, 1994) and mRNA levels
for proteasome subunits C2 and C5 were found to be increased in
extensor digitorum longus (EDL) muscles of rats starved for 2
days, as well as in soleus muscles undergoing denervation atrophy
(Medina et al, 1995). In addition, we have measured expression of
mRNA for the ubiquitin-conjugating enzyme (E214k). Expression
of mRNA has been quantitated using RT-competitive PCR, which
is based on competitive coamplification of the specific target
sequence with an internal standard sharing primer recognition
sites in one reaction tube (Auboeuf and Vidal, 1997). Quantitation
can then be performed by comparing the PCR signals of the
specific template with those obtained with known concentrations
of the competitor. Protein expression has also been determined by
immunoblotting, since it has been suggested that in various
cells elevated concentrations of mRNA of proteasome subunits
were not found to be accompanied by increased concentrations of
0
100
200
300
400
500
600
0 11 12 16 18 20 22 25 28
Weight loss (%)
Fl
uo
ro
m
et
ric
a
ct
iv
ity
 p
er
 
g 
pr
ot
ei
n
(%
 co
ntr
ol)
b c
 c
 c
0
50
100
150
200
C5
 (p
g 
g−
1
to
ta
l R
N
A)
C2
 (p
g 
g−
1
to
ta
l R
N
A)
b
c
a
0
20
40
60 b c c b
30 kDa
Weight loss (%)
Weight loss (%)
0
5000
10 000
15 000
20 000
Ba
nd
vo
lu
m
e
R2 = 0.8084
0
50
100
150
200
9 11.3 12 13.5 14 16 20
Weight loss (%)
M
us
cl
e
w
e
ig
ht
 (m
g)
b
0 10 12 15 17 25 27
Weight loss (%)
0 10 12 15 17 19 25
0 9 12 15 18 25
0 9 12 15 18 25
27
Weight loss (%)
A
B
C
D
E
F
Figure 3 (A) Proteasome proteolytic activity, as measured by the
‘chymotrypsin-like’ enzyme activity, in pectoral muscle of mice bearing the
MAC16 tumour and with different extents of weight loss. (B) Expression of
C5 mRNA and (C) expression of C2 mRNA in pectoral muscle from
cachectic mice bearing the MAC16 tumour. (D) Expression of 20S
proteasome a-subunits, determined by immunoblotting, in soluble extracts
of pectoral muscle from mice bearing the MAC16 tumour and different
extents of weight loss. (E) Densitometric analysis of band intensities in (D).
Differences from animals without weight loss are expressed as a, Po0.05,
b, Po0.01 and c o0.001. (F) Relationship between weight of pectoral
muscle and percentage weight loss.
19 kDa
Weight loss (%)
Weight loss (%)
0 9 12 15 18 25
0 9 12 15 18 25
Weight loss (%)
0 10 12 15 17 19 25 27
0
5000
10 000
15 000
20 000
25 000
30 000
35 000
Ba
nd
vo
lu
m
e
0
20
40
60
80
100
E2
 (p
g 
g−
1
to
ta
l R
N
A)
a
A
B
C
Figure 4 (A) Expression of E214k in soluble extracts of pectoral muscle
from mice bearing the MAC16 tumour and different extents of weight loss,
detected by immunoblotting. (B) Densitometric analysis of band intensities
in (A) reported in arbitary units. (C) Expression of E2 mRNA in pectoral
muscle of mice with different extents of mice loss. Differences from animals
without weight loss are expressed as a, Po 0.05.
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proteasomes (Kanayama et al, 1991; Shimbara et al, 1992). We
have also measured protein expression of E214k.
Using this approach, we have demonstrated a correlation
between increases in mRNA and protein expression of proteasome
a subunits in both gastrocnemius and pectoral muscle. We have
also demonstrated a correlation between E2 mRNA and protein
levels, although this was less strongly correlated with muscle
weight, suggesting that it was not rate-limiting for proteasome
proteolysis as might be predicted (Adegoke et al, 2002).
Proteasome expression and activity in both pectoral and gastro-
cnemius muscles increased progressively with increasing weight
loss up to about 20% followed by a decrease at higher weight loss,
except for C2 mRNA in pectoralis muscle, which remained
elevated. There was also a decrease in E2 expression at weight
losses greater than 20%. Proteasome specific total protein
degradation in gastrocnemius muscle, as determined by tyrosine
release in the presence of lactacystin, also peaked at 18– 20%
weight loss and then decreased. A similar rise and fall of the
ubiquitin-proteasome pathway was observed in psoas muscle of
alloxan-induced diabetic rabbits (Galban et al, 2001). Thus, the
activity increased 3 and 5 days after diabetes induction, but fell
down to control values by day 7, and thereafter decreased below
control. In pectoral muscle, both mRNA and protein for
proteasome a-subunits tended to increase with increasing weight
loss, suggesting a lack of coordination between synthesis of a and b
subunits. We have previously shown (Smith and Tisdale, 1993a)
that total body nitrogen and the nitrogen content of gastrocnemius
muscle decreases with increasing weight loss in mice bearing the
MAC16 tumour. The protein content of skeletal muscle is a balance
between the rate of protein synthesis and the rate of degradation.
Protein synthesis is depressed in muscle of weight-losing mice
bearing the MAC16 tumour, and this reduction in protein
synthesis may be the major factor contributing to loss of protein
at weight losses greater than 20%.
Using the release of tyrosine as a measure of muscle protein
degradation breakdown to detect serum factors from the MAC16
tumour that increase protein degradation, activity was found to
increase with increasing weight loss up to 20%, and with further
weight loss the activity was found to fall to a value not significantly
different from that found in animals without weight loss (Smith
and Tisdale, 1993b). This circulatory factor has now been isolated
and identified (Todorov et al, 1996) and shown to be a sulphated
glycoprotein of Mr 24 kDa called proteolysis factor (PIF), which
induces an increased expression of both proteasome subunits and
E2 in gastrocnemius muscle (Lorite et al, 2001). Proteolysis factor
has been shown to be responsible for the loss of skeletal muscle in
cachectic mice (Lorite et al, 1998). Using Western blotting to
detect urinary PIF in mice bearing the MAC16 tumour, excretion
levels were found to be maximal at weight loss between 20 and 22%
(Figure 5). This pattern parallels changes in expression of
proteasome subunits in both gastrocnemius and pectoral muscle
suggesting that PIF is responsible for the upregulation of the
ubiquitin-proteasome pathway. Expression of C2 and C5 mRNA in
rectus abdominis muscle of cachectic cancer patients was also
found to be maximal at a weight loss of 12 –19% (Khal et al, 2005).
The rate of muscle catabolism, as measured by phenylalanine
release, in a rat model of cachexia was also highest at small tumour
burdens and decreased as the tumour grew larger (de Blaauv et al,
1997). This appeared to be caused by the loss of capacity of the
tumour to further break down muscle. The reason for this is not
known, but it may be that as the tumour grows and becomes
necrotic cells capable of synthesizing PIF are lost. Alternatively, the
tumour microenvironment may not be conducive to the synthesis
of a highly glycosylated peptide.
The mechanism for the loss of protein in gastrocnemius muscle
at weight losses greater than 20% requires further investigation,
but the lack of bioactivity of serum from mice bearing the MAC16
tumour at weight losses of 20–25% (Smith and Tisdale, 1993b)
suggests that a circulatory factor is not responsible for the protein
degradation, and the present results suggest that the ubiquitin-
proteasome pathway alone cannot account for the high level of
protein breakdown. This suggests that depression of protein
synthesis may be more important than an increase in protein
degradation at high weight loss.
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